WASHINGTON, DC — The Biosimilars Council applauds the unanimous Senate passage of the Affordable Prescriptions for Patients Act led by Senator Cornyn (R-TX) and Senator Blumenthal (D-CT). The bill is aimed at reforming patent abuse in the pharmaceutical industry.“The Biosimilars Council and AAM applauds unanimous Senate passage of the Cornyn-Blumenthal legislation,” said Craig Burton, executive director of the biosimilars council. “Patent thickets are used by brand pharmaceutical companies to maintain high prices and deny patients access to lower-cost medicines. This legislation is a great step in curbing these abuses and will help increase competition and access for biosimilars. We encourage the House to take up this legislation and for Congress to continue working to help lower costs for patients.”
Biosimilars Council applauds patent abuse act
The Biosimilars Council applauds the unanimous Senate passage of the Affordable Prescriptions for Patients Act led by Senator Cornyn (R-TX) and Senator Blumenthal (D-CT). The bill is aimed at reforming patent abuse in the pharmaceutical industry.
Related
NCPA: PBM Reform Act must pass ASAP
Systemic changes like those in the PBM Reform Act must pass and be enacted as soon as possible. We’re grateful for this bill’s introduction and will do everything we can to push it across the finish line.”
NACDS hails introduction of Pharmacy Benefit Manager Reform Act of 2025
The bill establishes powerful transparency requirements, bans spread pricing, assures fair reimbursement for pharmacies, and tackles anti-competitive practices that have driven up drug costs and limited patient choice.
Patent thickets and litigation abuses hinder all biosimilars
White paper analyzes problems and solutions to patent abuses.
Clover Health launches New Jersey Community Pharmacy Program in partnership with IPC’s iCare+ Network
The program will be anchored by IPC’s iCare+ Independent Pharmacy Network, which includes thousands of community-rooted pharmacies nationwide and many in New Jersey.
Latest
NRF's 2025 Top 100 Retailers little changed from last year
Kantar’s David Marcotte noted that year-over-year continuity at the top underscores the market dominance of large-format retailers and vertically integrated omnichannel players.
Ferrero reportedly will buy Kellogg for $3 billion
The Journal reported that WK Kellogg shareholders will receive $23 per share in cash—representing a premium of roughly 40% over recent trading levels. Including debt, the transaction gives WK Kellogg a total enterprise value of about $3.1 billion.
NCPA: PBM Reform Act must pass ASAP
Systemic changes like those in the PBM Reform Act must pass and be enacted as soon as possible. We’re grateful for this bill’s introduction and will do everything we can to push it across the finish line.”
NACDS hails introduction of Pharmacy Benefit Manager Reform Act of 2025
The bill establishes powerful transparency requirements, bans spread pricing, assures fair reimbursement for pharmacies, and tackles anti-competitive practices that have driven up drug costs and limited patient choice.